WHO Issues Concern Over Critical Scarcity of Weight-Loss Injections

Under a tenth of patients that would benefit from obesity jabs like Wegovy can access them, warns the WHO as it issues its initial recommendations on the medications.

With over a billion individuals worldwide now classified as obese, it is calling for increased and just access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"The latest guidance affirms that obesity is a lifelong illness that can be treated with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are key barriers to universal access to the treatments that can assist patients in reducing substantial body mass, says the organization.

Skinny Jab Shortage

Even in the present most favorable case, the production of such drugs would only suffice for approximately 100 million people – under 10% of eligible patients, as stated by the health organization.

The recommendation encourages nations and manufacturers to widen availability, by approaches such as licensing agreements.

A patent on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in multiple countries in 2026.

How Weight-Loss Injections Work

These medications imitate a biological compound to slow digestion, suppress the appetite and enhance satiety so people eat less.

Individuals typically see weight reduction in the initial weeks of beginning the regular doses.

Studies suggests people may put most of the weight back on a year later of stopping the medication, when their normal appetite return.

Being overweight or obese raises your chance for experiencing diseases, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies.

Obesity affects people in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.